DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for mitral valve stenosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMitral valve stenosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mitral valve stenosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adrenoceptor beta 1 (ADRB1) — ADRB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3s,8s,9s,12sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9L84 · 3.22 Å · ligand (3S,8S,9S,12S)-3,12-BIS(1,1-DIMETHYLETHYL)-8-HYDROXY-4,11-DIOXO-9-(PHENYLMETHYL)-6-[[4-(2-PYRIDINYL)PHENYL]METHYL]-2,5,
6,10,13-PENTAAZATETRADECANEDIOIC ACID DIMETHYL ESTER (DR7). Experimental structure, not a prediction.
What the evidence adds up to
A 1961 paper reviewing the first decade of surgical treatment for mitral stenosis notes that while increasing the valve orifice could arrest or reverse the pathophysiological patterns of the disease, surgery had important limitations. Under closed-heart techniques, effective reconstitution of structure and function proved difficult or impossible when extensive calcification and fusion rendered the valve exceptionally distorted, and there was a constant hazard of inadvertently creating valvular incompetence. A 1952 diagnostic clinic presents two patients to illustrate the indications, contraindications and results of direct commissurotomy for mitral stenosis.
A 2018 prospective study of 179 men and 354 women, of whom 84 had mitral stenosis with a valve area ≤1.5 cm², found that patients with mitral stenosis had a smaller aortic annulus and sinotubular junction in univariate analysis. Multivariate analysis indicated that mitral stenosis was correlated with a smaller indexed size of the aortic annulus, yielding a regression coefficient of 0.541 (p=0.005). The authors state it is not yet clarified whether this occurs due to chronic low stroke volume or involvement of the aortic annulus in the fibrotic process.
Two review papers, from 2007 and 2024, address the genetics of mitral valve prolapse, not mitral stenosis. The 2007 review reports linkage to sites on chromosomes 11, 13 and 16 and identification of the first mutation in familial mitral valve prolapse, an X-linked filamin A mutation. The 2024 review, after analysing 83 selected publications from 3291 dealing with mitral valve embryology, advocates for the importance of a gene-based therapy that should be available soon to prevent or treat valvular degeneration non-invasively. Neither review provides data on any drug treatment for mitral stenosis.
What is missing is any clinical trial of a drug for mitral stenosis, any evidence that a genetic approach has moved beyond advocacy into human testing, and any clarification of whether the observed aortic root changes in mitral stenosis are clinically relevant or merely an anatomical correlation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Cardiology · 2007 · 30 citations
Molecular genetics of mitral valve prolapse
AbstractPURPOSE OF REVIEW: Mitral valve prolapse is a common disorder with a strong hereditary component. It is associated with important mitral regurgitation requiring surgical repair and other clinical complications. Genetic studies can provide clues to mechanism and therapy. RECENT FINDINGS: Advances in phenotypic classification have led to linkage to sites on chromosomes 11, 13 and 16 and identification of the first mutation in familial mitral valve prolapse not related to connective tissue syndromes - an X-linked filamin A mutation. New understanding of mechanism based on studies in a mouse Marfan model emphasize the dynamic interplay of differentiating cells and growth factors, with strong potential for therapy. SUMMARY: This new knowledge brings us closer to the ultimate goal of preventing the progression of mitral valve disease to the stage of clinical expression.
Pathology - Research and Practice · 2024 · 3 citations · open access
Update on the genetic profile of mitral valve development and prolapse
AbstractThe purpose of this review is to present a comprehensive overview of the literature published up to February 2024 on the PubMed database regarding the development of mitral valve disease, with detailed reference to mitral valve prolapse, from embryology to a genetic profile. Out of the 3291 publications that deal with mitral valve embryology, 215 refer to mitral valve genetics and 83 were selected for further analysis. After reviewing these data, we advocate for the importance of a gene-based therapy that should be available soon, to prevent or treat non-invasively the valvular degeneration.
MITRAL INSUFFICIENCY FOLLOWING OPERATION FOR MITRAL STENOSIS
AbstractMore than a decade has passed since the development of modern techniques for the surgical treatment of mitral stenosis. During this relatively brief interval a remarkable experience has been gained in the indications for and the response to surgical intervention. Almost at the outset it was demonstrated that a satisfactory increase in the size of the valve orifice could arrest or reverse the pathophysiological patterns of mitral stenosis. However, it also became quite clear with time, even to the most enthusiastic protagonists, that surgery had important limitations. Under the restrictions imposed by closed heart techniques, an effective reconstitution of structure and function proved difficult, if not impossible, when extensive calcification and fusion rendered the valve exceptionally distorted and misshapen. The issue was always compounded under these circumstances and even under more favorable ones by the constant hazard of inadvertently creating valvular incompetence. Actually the frequency with which the clinical manifestations of
Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · 2018 · 0 citations · open access
The association of severe mitral stenosis and the size of the aortic root and ascending thoracic aorta
AbstractOBJECTIVE: The aim of this study was to examine the role of isolated rheumatic mitral stenosis (MS) in remodeling of the aorta at various locations. METHODS: In this prospective study, patients who were to undergo transesophageal echocardiography for various indications were screened. The study participants were classified into 2 groups according to the presence of MS with a valve area ≤1.5 cm2. Factors associated with the index dimensions of the aorta at the levels of the annulus, root, sinotubular junction (STJ), and the proximal ascending portion (5 cm from the annulus) were evaluated. Multivariate linear models were constructed including factors that affect the size of the aorta at any of the aforementioned levels. Pearson's correlation coefficient was used to investigate the association between mitral valve area, mitral valve gradient, and dimensions of the aorta. RESULTS: A total of 179 men and 354 women were enrolled. Eighty-four patients had MS (15.8%). The patients with MS were younger and less likely to have hypertension. In univariate analysis, patients with MS had a smaller annulus and STJ (p=0.003 and p=0.043, respectively). Multivariate analysis indicated that MS was correlated with a smaller indexed size of the aortic annulus, yielding a regression coefficient value of 0.541 (p=0.005). CONCLUSION: The presence of significant stenosis at the level of the mitral valve is associated with a smaller diameter in the aortic annulus. It is yet to be clarified whether this phenomenon occurs due to chronic, long-standing, low stroke volume or involvement of the aortic annulus in the fibrotic process of mitral disease.
AbstractMitral stenosis forms the chief subject of this diagnostic clinic. The history of surgery for mitral stenosis is briefly reviewed, together with a discussion of the indirect and direct surgical approaches to the problem. Two patients are presented to illustrate the indications, contraindications and results of direct attack (commissurotomy) on the stenotic mitral valve.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
